NEW YORK (GenomeWeb News) – Clinical Data said today it has initiated a long-term safety study for its depression treatment drug Vilazodone.
 
The company said the safety study will support a new drug application it expects to file with the US Food and Drug Administration in 2009. The study will test the long-term safety and tolerability of Vilazodone and will enroll patients at 40 sites in the US.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.